Data gathered: November 27
Alternative Data for Elicio Therapeutics
| Alternative Data | Value | 3m Change | Trend | Benchmark |
|---|---|---|---|---|
| Sentiment | 92 | Sign up | Sign up | Sign up |
| Webpage traffic | 6,000 | Sign up | Sign up | Sign up |
| Google Trends | 9 | Sign up | Sign up | Sign up |
| 4chan Mentions | N/A | Sign up | Sign up | Sign up |
| Reddit Mentions | N/A | Sign up | Sign up | Sign up |
| Stocktwits Mentions | N/A | Sign up | Sign up | Sign up |
| Stocktwits Subscribers | 252 | Sign up | Sign up | Sign up |
| Twitter Mentions | 11 | Sign up | Sign up | Sign up |
| News Mentions | N/A | Sign up | Sign up | Sign up |
| Customer reviews | N/A | Sign up | Sign up | Sign up |
About Elicio Therapeutics
None
| Price | $5.05 |
| Target Price | Sign up |
| Volume | 11,360 |
| Market Cap | $54M |
| Year Range | $3.39 - $10.4 |
| Dividend Yield | 0% |
| PE Ratio | 5.75 |
| Analyst Rating | 100% buy |
| Industry | Biotechnology |
In the news
 |
Elicio Therapeutics: Q3 Earnings SnapshotNovember 13 - Yahoo |
 |
Elicio Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate UpdatesNovember 13 - Yahoo |
|
Elicio Therapeutics Presents Updated Translational Data from ELI-002 Phase 1 AMPLIFY-7P Study at the Society for Immunotherapy of Cancer (“SITC”) 2024 Annual MeetingNovember 7 - Yahoo |
|
Elicio Therapeutics to Present Clinical Data at the Society for Immunotherapy of Cancer (SITC) 2024 Annual Meeting and Stand Up to Cancer (SU2C) Innovation SummitOctober 30 - Yahoo |
Elicio Therapeutics initiated with a Buy at JonesResearchOctober 29 - TipRanks |
|
Elicio Therapeutics initiated with bullish view at JonesResearch, here's whyOctober 29 - Thefly.com |
|
Financial performance View All
| Revenue | Cost of Revenue | Gross Profit | Net Income | ebitda | EPS | |
|---|---|---|---|---|---|---|
| Q3 '24 | 0 | 3.1M | -3.1M | -19M | 0 | -1.390 |
| Q2 '24 | 27,000 | 2.7M | -2.8M | -7.2M | -11M | -0.640 |
| Q1 '24 | 120,000 | 2.7M | -2.6M | -12M | -10M | -1.150 |
| Q4 '23 | 250,000 | 3.2M | -3M | -8.9M | -9M | -1.750 |
| Q3 '23 | 0 | 3.5M | -3.6M | -11M | -11M | -1.270 |
Insider Transactions View All
| GKCC, LLC filed to buy 3,442,341 shares at $5.8. August 14 '24 |
| Venkatesan Jay filed to buy 50,000 shares at $5. July 2 '24 |
| GKCC, LLC filed to buy 1,600,000 shares at $5. July 2 '24 |
| GKCC, LLC filed to buy 1,032,702 shares at $5.8. March 20 '24 |
| GKCC, LLC filed to buy 1,915,639 shares at $5.8. December 26 '23 |
Similar companies
Read more about Elicio Therapeutics (ELTX) and their ai stock analysis, price prediction, earnings, congress trading, insider transactions, technical analysis, sentiment, webpage traffic, google trends, 4chan mentions, reddit mentions, stocktwits mentions, stocktwits subscribers, twitter mentions, news mentions & customer reviews.
What is the Market Cap of Elicio Therapeutics?
The Market Cap of Elicio Therapeutics is $54M.
What is Elicio Therapeutics' PE Ratio?
As of today, Elicio Therapeutics' PE (Price to Earnings) ratio is 5.75.
What is the current stock price of Elicio Therapeutics?
Currently, the price of one share of Elicio Therapeutics stock is $5.05.
How can I analyze the ELTX stock price chart for investment decisions?
The ELTX stock price chart above provides a comprehensive visual representation of Elicio Therapeutics' stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling Elicio Therapeutics shares. Our platform offers an up-to-date ELTX stock price chart, along with technical data analysis and alternative data insights.
Does ELTX offer dividends to its shareholders?
As of our latest update, Elicio Therapeutics (ELTX) does not offer dividends to its shareholders. Investors interested in Elicio Therapeutics should consider the potential for capital appreciation as the primary return on investment, rather than expecting dividend payouts.
What are some of the similar stocks of Elicio Therapeutics?
Some of the similar stocks of Elicio Therapeutics are Amgen, Gilead Sciences, Catalyst Pharmaceuticals, Inovio Pharmaceuticals, and Anavex Life Sciences.
.